Tagrisso 80 MG tablet 30S
Ended Awarded
- Contract number
- SPE2DB25FBGL8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $21,325
Award facts
- Contract value 100% obligated
- $21,325.14 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded on August 27, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of Tagrisso 80 mg tablets (30-count units) with a ceiling value of $21,325.14 under firm fixed pricing. The contract, which is not set-aside and was competitively awarded, specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 18, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of medications and medical supplies to support military healthcare programs globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's Medical Supply Chain. The company's contract portfolio demonstrates extensive capabilities in fulfilling diverse pharmaceutical needs across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical devices. This specific delivery order for Tagrisso—a targeted cancer therapy—reflects AmerisourceBergen's role in supporting the Defense Health Agency and broader military healthcare systems with oncology and other specialized pharmaceutical products.
Quick answers
Who was awarded contract SPE2DB25FBGL8?
SPE2DB25FBGL8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on August 27, 2025.
How much is contract SPE2DB25FBGL8 worth?
The government has obligated $21,325 on SPE2DB25FBGL8.
Is contract SPE2DB25FBGL8 an order under another contract?
Yes. SPE2DB25FBGL8 is a delivery order under SPE2DB22D3016, an indefinite delivery contract.
Was contract SPE2DB25FBGL8 competed?
The extent of competition for SPE2DB25FBGL8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award